Nadroparin

Generic Name
Nadroparin
Brand Names
Fraxiparine
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
1K5KDI46KZ
Background

Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Indication

Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.

Associated Conditions
Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction, Thromboembolic phenomena
Associated Therapies
-

Heparin for Pregnant Women With Thrombophilia

First Posted Date
2009-11-25
Last Posted Date
2009-11-25
Lead Sponsor
Medical University of Vienna
Target Recruit Count
300
Registration Number
NCT01019655
Locations
🇦🇹

Department of Obstetrics and Gynecology, Vienna, Austria

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

First Posted Date
2009-08-04
Last Posted Date
2012-02-01
Lead Sponsor
Italfarmaco
Target Recruit Count
1166
Registration Number
NCT00951574
Locations
🇮🇹

Salvatore Maugeri Foundation, Pavia, Italy

🇮🇹

Hematology and Oncology Department, Piacenza, Italy

🇮🇹

Medical Oncology Department Regina Elena Institute, Roma, Italy

and more 22 locations

Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures

First Posted Date
2009-04-15
Last Posted Date
2012-12-18
Lead Sponsor
Red Cross Hospital Beverwijk
Target Recruit Count
669
Registration Number
NCT00881088
Locations
🇳🇱

Medical Center Alkmaar, Alkmaar, North Holland, Netherlands

🇳🇱

University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands

🇳🇱

Red Cross Hospital, Beverwijk, N-Holland, Netherlands

and more 2 locations

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

First Posted Date
2009-02-13
Last Posted Date
2016-03-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1351
Registration Number
NCT00843492
Locations
🇪🇸

GSK Investigational Site, Vigo/Pontevedra, Spain

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

First Posted Date
2008-11-24
Last Posted Date
2008-11-24
Lead Sponsor
Beijing Chao Yang Hospital
Target Recruit Count
274
Registration Number
NCT00796692
Locations
🇨🇳

The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

🇨🇳

The Affiliated Hospital of Medical College Jining, Jining, Shandong, China

🇨🇳

The Affiliated Hospital of Shenyang Medical University, Shenyang, Liaoning, China

and more 36 locations

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-04-07
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
503
Registration Number
NCT00312013
Locations
🇸🇮

GSK Investigational Site, Ljubljana, Slovenia

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

Terminated
Conditions
First Posted Date
2006-03-16
Last Posted Date
2006-03-16
Lead Sponsor
University Hospital, Geneva
Registration Number
NCT00303407
Locations
🇨🇭

Center of Continuous Care, chemin de la Savonnière, Collonge-Bellerive (Geneva), Geneva, Switzerland

Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration

First Posted Date
2006-02-03
Last Posted Date
2009-08-26
Lead Sponsor
Onze Lieve Vrouwe Gasthuis
Target Recruit Count
215
Registration Number
NCT00286273
Locations
🇳🇱

Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

© Copyright 2024. All Rights Reserved by MedPath